One Ventures

OneVentures is a leading Australian venture capital firm with a global focus, investing in technology and healthcare companies. The firm provides both equity and credit funding, with a particular emphasis on innovative products addressing significant market needs. OneVentures operates through several funds. Their Growth Fund V, which closed at $142 million, focuses on technology and tech-enabled companies, investing up to $20 million per company. This fund targets global themes such as remote work, digitization, clean energy, and healthcare. Additionally, the firm manages the Growth Credit Fund IV and the VGF Credit Fund, providing debt financing to high-growth tech companies, with investments ranging from $500,000 to $10 million per company. In the healthcare sector, OneVentures manages the $170 million Healthcare Fund III, investing in therapeutics, devices, and diagnostics with a clear commercial pathway. This fund is part of the Commonwealth Government’s Biomedical Translation Fund program, aiming to advance promising biomedical innovations. OneVentures' portfolio includes companies like Vaxxas, which develops needle-free vaccine delivery technology, and BiVACOR, known for its artificial heart technology. The firm is known for its hands-on approach, providing strategic guidance and leveraging its extensive network to support the growth and success of its portfolio companies.